CLINICAL_TRIALS
trial_result
· 2020-10-27
Clinical Trial Update: A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC [Phase 2]
Summary
Phase 2 trial comparing tivozanib versus sunitinib in metastatic renal cell carcinoma has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-10-27